CVS Health January, 2020
Troy Brennan, M.D., Sree Chaguturu, M.D., Daniel Knecht, M.D.

Introduction

After many years of scientific promise but few real results, gene therapies are now a reality. These exciting new interventions have the potential to relieve tremendous suffering for patients with genetic disorders. Making sure these treatments are accessible for all those who need them requires innovative partnerships, as well as new ways of providing health insurance and pharmacy benefit design.

Generally speaking, gene therapies use a target gene that expresses protein products at a sufficient level to cure, or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Patient / Consumer, Payer, Precision Medicine, Provider, Retail care, Technology
Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA
Cerevel Parkinson’s data adds lustre to AbbVie acquisition
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more
Recursion, Canaan, Metsera and more—Chutes & Ladders

Share This Article